Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

Laura Calvillo, Roberto Latini, Jan Kajstura, Annarosa Leri, Piero Anversa, Pietro Ghezzi, Monica Salio, Anthony Cerami, Michael Brines

Research output: Contribution to journalArticlepeer-review


Erythropoietin (EPO), originally identified for its critical hormonal role in promoting erythrocyte survival and differentiation, is a member of the large and diverse cytokine superfamily. Recent studies have identified multiple paracrine/autocrine functions of EPO that coordinate local responses to injury by maintaining vascular autoregulation and attenuating both primary (apoptotic) and secondary (inflammatory) causes of cell death. Experimental evidence also supports a role for EPO in repair and regeneration after brain and spinal cord injury, including the recruitment of stem cells into the region of damage. Tissue expression of the EPO receptor is widespread, especially during development, and includes the heart. However, it is currently unknown as to whether EPO plays a physiological function in adult myocardial tissue. We have assessed the potential protective role of EPO in vitro with adult rat cardiomyocytes, and in vivo in a rat model of myocardial infarction with reperfusion. The results show that EPO markedly prevents the apoptosis of cultured adult rat myocardiocytes subjected to 28 h of hypoxia (≈3% normal oxygen). Additional studies employing a rat model of coronary ischemia-reperfusion showed that the administration of recombinant human EPO (5,000 units/kg of body weight; i.p. daily for 7 days) reduces cardiomyocyte loss by ≈50%, an extent sufficient to normalize hemodynamic function within 1 week after reperfusion. These observations not only suggest a potential therapeutic role for recombinant human EPO in the treatment of myocardial ischemia and infarction by preventing apoptosis and attenuating postinfarct deterioration in hemodynamic function, but also predict that EPO is likely a tissue-protective cytokine in other organs as well.

Original languageEnglish
Pages (from-to)4802-4806
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number8
Publication statusPublished - Apr 15 2003

ASJC Scopus subject areas

  • Genetics
  • General


Dive into the research topics of 'Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling'. Together they form a unique fingerprint.

Cite this